中国医药子公司获富马酸伏诺拉生化学原料药上市申请批准通知书

Core Viewpoint - China Pharmaceutical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the listing application of fumaric acid venlafaxine, which is primarily used to treat gastroesophageal reflux disease and eradicate Helicobacter pylori when used in conjunction with appropriate antibiotics [1] Group 1 - Tianfang Pharmaceutical's approval for fumaric acid venlafaxine indicates that the raw material meets domestic drug registration requirements and has been approved for use in domestic formulations [1] - The approval of this raw material will further solidify the company's integrated development strategy of raw materials and formulations [1] - This development will expand the company's product range and accumulate valuable experience for future raw material drug applications [1]